Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash from Financing Activities (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Cash from Financing Activities for 6 consecutive years, with $443000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 7483.33% to $443000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Dec 2025, up 9639.41% year-over-year, with the annual reading at $19.8 million for FY2025, 9639.41% up from the prior year.
  • Cash from Financing Activities hit $443000.0 in Q4 2025 for Rapid Micro Biosystems, down from $19.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $139.3 million in Q3 2021 to a low of -$1.4 million in Q2 2021.
  • Historically, Cash from Financing Activities has averaged $11.9 million across 5 years, with a median of $74000.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 2786080.0% in 2021 and later tumbled 2880.0% in 2025.
  • Year by year, Cash from Financing Activities stood at -$1.3 million in 2021, then skyrocketed by 106.93% to $87000.0 in 2022, then plummeted by 113.79% to -$12000.0 in 2023, then skyrocketed by 50.0% to -$6000.0 in 2024, then surged by 7483.33% to $443000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for RPID at $443000.0 in Q4 2025, $19.2 million in Q3 2025, and -$298000.0 in Q2 2025.